Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer

• Published in: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Vol. 16; no. 2; p. e1950
• Main Authors: Cao, Ye, Meng, Fansu, Cai, Tiange, Gao, Lanwen, Lee, Jaiwoo, Solomevich, Sergey O, Aharodnikau, Uladzislau E, Guo, Tingting, Lan, Meng, Liu, Fengjie, Li, Qianwen, Viktor, Timoshenko, Li, Detang, Cai, Yu
• Format: Journal Article
• Language: English
• Published: United States 01.03.2024
• Subjects: Antineoplastic Agents - therapeutic use; Drug Delivery Systems; Humans; Nanomedicine; Nanoparticle Drug Delivery System; Nanoparticles - therapeutic use; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - pathology; Tumor Microenvironment; tumor microenvironment (TME); drug resistance; triple‐negative breast cancer (TNBC); metastasis; nanoparticle (NP)‐based drug delivery systems
• ISSN: 1939-0041
• DOI: 10.1002/wnan.1950

The conventional therapeutic treatment of triple-negative breast cancer (TNBC) is negatively influenced by the development of tumor cell drug resistant, and systemic toxicity of therapeutic agents due to off-target activity. In accordance with research findings, nanoparticles (NPs) responsive to the tumor microenvironment (TME) have been discovered for providing opportunities to selectively target tumor cells via active targeting or Enhanced Permeability and Retention (EPR) effect. The combination of the TME control and therapeutic NPs offers promising solutions for improving the prognosis of the TNBC because the TME actively participates in tumor growth, metastasis, and drug resistance. The NP-based systems leverage stimulus-responsive mechanisms, such as low pH value, hypoxic, excessive secretion enzyme, concentration of glutathione (GSH)/reactive oxygen species (ROS), and high concentration of Adenosine triphosphate (ATP) to combat TNBC progression. Concurrently, NP-based stimulus-responsive introduces a novel approach for drug dosage design, administration, and modification of the pharmacokinetics of conventional chemotherapy and immunotherapy drugs. This review provides a comprehensive examination of the strengths, limitations, applications, perspectives, and future expectations of both novel and traditional stimulus-responsive NP-based drug delivery systems for improving outcomes in the medical practice of TNBC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.